Jazz Pharmaceuticals JAZZ Other comprehensive income/(loss)
Other comprehensive income/(loss) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other comprehensive income/(loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other comprehensive income/(loss)?
- Jazz Pharmaceuticals (JAZZ) reported other comprehensive income/(loss) of -$82.4M in Q1 2026.
- How has Jazz Pharmaceuticals's other comprehensive income/(loss) changed year-over-year?
- Jazz Pharmaceuticals's other comprehensive income/(loss) decreased by 150.9% year-over-year, from $162M to -$82.4M.
- What is the long-term trend for Jazz Pharmaceuticals's other comprehensive income/(loss)?
- Over 3 years (2021 to 2025), Jazz Pharmaceuticals's other comprehensive income/(loss) has grown at a 12.5% compound annual growth rate (CAGR), from -$266.01M to $379.01M.
- What does other comprehensive income/(loss) mean?
- Total gains and losses that bypass the income statement and go directly to equity.
- How do you interpret other comprehensive income/(loss)?
- A positive value indicates an increase in shareholder equity from non-operating sources, while a negative value indicates a decrease.
- How does other comprehensive income/(loss) compare across companies?
- Standardized reporting requirement; varies based on the company's exposure to global markets and financial derivatives.